144 related articles for article (PubMed ID: 11697841)
1. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Köstler WJ; Brodowicz T; Attems Y; Hejna M; Tomek S; Amann G; Fiebiger WC; Wiltschke CH; Krainer M; Zielinski CC
Ann Oncol; 2001 Sep; 12(9):1281-8. PubMed ID: 11697841
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.
Brodowicz T; Köstler WJ; Wiltschke C; Zielinski CC
Am J Clin Oncol; 1999 Oct; 22(5):535. PubMed ID: 10521076
[No Abstract] [Full Text] [Related]
3. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
Verweij J; Lee SM; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola ED; van Glabbeke M; Tonelli D; Judson IR
J Clin Oncol; 2000 May; 18(10):2081-6. PubMed ID: 10811673
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
5. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
van Hoesel QG; Verweij J; Catimel G; Clavel M; Kerbrat P; van Oosterom AT; Kerger J; Tursz T; van Glabbeke M; van Pottelsberghe C
Ann Oncol; 1994 Jul; 5(6):539-42. PubMed ID: 7918126
[TBL] [Abstract][Full Text] [Related]
6. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
Gebbia V; Borsellino N; Testa A; Tirrito ML; Ferrera P; Colombo A; Mauceri G; Marrazzo A; Porretto F; Musso M
Breast Cancer Res Treat; 2003 Jan; 77(2):99-108. PubMed ID: 12602908
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel.
Ishitobi M; Shin E; Kikkawa N
Int J Clin Oncol; 2001 Feb; 6(1):55-8. PubMed ID: 11706529
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
[TBL] [Abstract][Full Text] [Related]
11. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
12. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.
Verweij J
Anticancer Drugs; 1995 Jul; 6 Suppl 4():19-24. PubMed ID: 8745350
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
16. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Brodowicz T; Koestler WJ; Tomek S; Vaclavik I; Herscovici V; Wiltschke C; Steger GG; Zielinski CC
Anticancer Drugs; 2000 Mar; 11(3):149-53. PubMed ID: 10831273
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Aravantinos G; Bafaloukos D; Fountzilas G; Christodoulou C; Papadimitriou C; Pavlidis N; Kalofonos HP; Gogas H; Kosmidis P; Dimopoulos MA
Ann Oncol; 2003 Jul; 14(7):1094-9. PubMed ID: 12853352
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
